Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study

Table 4 Changes in serum fat metabolic markers from baseline to 8 weeks in the Placebo and in LI85008F supplemented group

Parameter	Study Period	Placebo (x ± SE)	P value^a	LI85008F (x ± SE)	P value^a	(P value)^b
Cholesterol (mM/L)	Baseline	5.33 ± 0.23	0.1176	5.58 ± 0.25	0.6479	-
	8 week	5.64 ± 0.22	0.1176	5.48 ± 0.24	0.6479	-
	Change	−0.32 ± 0.19	-	0.09 ± 0.20	-	0.149
HDL-Cholesterol (mM/L)	Baseline	2.18 ± 0.05	0.5812	2.12 ± 0.08	0.2192	-
	8 week	2.14 ± 0.05	0.5812	2.23 ± 0.07	0.2192	-
	Change	0.04 ± 0.07	-	−0.11 ± 0.09	-	0.11
LDL-Cholesterol (mM/L)	Baseline	9.03 ± 0.28	0.0925	9.21 ± 0.29	0.0005	-
	8 week	8.41 ± 0.28	0.0925	7.67 ± 0.28	0.0005	-
	Change	0.62 ± 0.35	-	1.53 ± 0.37	-	0.0834
Triglycerides (mM/L)	Baseline	0.33 ± 0.01	0.8148	0.32 ± 0.02	0.0389	-
	8 week	0.33 ± 0.01	0.8148	0.29 ± 0.01	0.0389	-
	Change	0.00 ± 0.01	-	0.03 ± 0.02	-	0.063
Glucose (mM/L)	Baseline	6.98 ± 0.61	0.8726	6.88 ± 0.35	0.0033	-
	8 week	6.91 ± 0.57	0.8726	5.93 ± 0.27	0.0033	-
	Change	0.07 ± 0.41	-	0.94 ± 0.28	-	0.0669

^a Difference within the group (baseline vs. final evaluation) using paired t-test.
^b Difference between changes (derived from baseline minus final evaluation) in placebo and LI85008F group using unpaired t-test.

ISSN: 1476-511X